Last reviewed · How we verify
Arthcal BAKUCHIOL FACE SERUM (BAKUCHIOL)
BAKUCHIOL, marketed as Arthcal BAKUCHIOL FACE SERUM by Beijing JUNGE Technology Co., Ltd., is a topical skincare product that has gained market presence through its retinoid-like effects without the associated irritation. Its key strength lies in its mechanism of promoting cell turnover and collagen production, offering a gentler alternative to traditional retinoids. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic formulations.
At a glance
| Generic name | BAKUCHIOL |
|---|---|
| Sponsor | Beijing JUNGE Technology Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging (PHASE2)
- The Efficacy of Bakuchiol in Treating PIH (NA)
- A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging (NA)
- Comparison of the Cosmetic Effects of Bakuchiol and Retinol (EARLY_PHASE1)
- Double-blinded, Vehicle Controlled Study to Evaluate Efficacy & Tolerance of Bakuchiol and Ethyl Linoleate on Acne (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arthcal BAKUCHIOL FACE SERUM CI brief — competitive landscape report
- Arthcal BAKUCHIOL FACE SERUM updates RSS · CI watch RSS
- Beijing JUNGE Technology Co., Ltd. portfolio CI